Publications
Detailed Information
Targeting tyrosine kinases for treatment of ocular tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jo, Dong Hyun | - |
dc.contributor.author | Kim, Jin Hyoung | - |
dc.contributor.author | Kim, Jeong Hun | - |
dc.date.accessioned | 2023-04-25T07:31:51Z | - |
dc.date.available | 2023-04-25T07:31:51Z | - |
dc.date.created | 2019-10-04 | - |
dc.date.created | 2019-10-04 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.citation | Archives of Pharmacal Research, Vol.42 No.4, pp.305-318 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191506 | - |
dc.description.abstract | Uveal melanoma is the most common intraocular primary malignant tumor in adults, and retinoblastoma is the one in children. Current mainstay treatment options include chemotherapy using conventional drugs and enucleation, the total removal of the eyeball. Targeted therapies based on profound understanding of molecular mechanisms of ocular tumors may increase the possibility of preserving the eyeball and the vision. Tyrosine kinases, which modulate signaling pathways regarding various cellular functions including proliferation, differentiation, and attachment, are one of the attractive targets for targeted therapies against uveal melanoma and retinoblastoma. In this review, the roles of both types of tyrosine kinases, receptor tyrosine kinases and non-receptor tyrosine kinases, were summarized in relation with ocular tumors. Although the conventional treatment options for uveal melanoma and retinoblastoma are radiotherapy and chemotherapy, respectively, specific tyrosine kinase inhibitors will enhance our armamentarium against them by controlling cancer-associated signaling pathways related to tyrosine kinases. This review can be a stepping stone for widening treatment options and realizing targeted therapies against uveal melanoma and retinoblastoma. | - |
dc.language | 영어 | - |
dc.publisher | 대한약학회 | - |
dc.title | Targeting tyrosine kinases for treatment of ocular tumors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s12272-018-1094-3 | - |
dc.citation.journaltitle | Archives of Pharmacal Research | - |
dc.identifier.wosid | 000465858400003 | - |
dc.identifier.scopusid | 2-s2.0-85057113056 | - |
dc.citation.endpage | 318 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 305 | - |
dc.citation.volume | 42 | - |
dc.identifier.kciid | ART002473136 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Jo, Dong Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Jeong Hun | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ENDOTHELIAL-GROWTH-FACTOR | - |
dc.subject.keywordPlus | METASTATIC UVEAL MELANOMA | - |
dc.subject.keywordPlus | FOCAL ADHESION KINASE | - |
dc.subject.keywordPlus | FACTOR-I RECEPTOR | - |
dc.subject.keywordPlus | C-MET | - |
dc.subject.keywordPlus | IMATINIB MESYLATE | - |
dc.subject.keywordPlus | FACTOR VEGF | - |
dc.subject.keywordPlus | CLINICOPATHOLOGICAL PARAMETERS | - |
dc.subject.keywordPlus | RETINOBLASTOMA CELLS | - |
dc.subject.keywordPlus | SIGNALING PATHWAYS | - |
dc.subject.keywordAuthor | Retinoblastoma | - |
dc.subject.keywordAuthor | Uveal melanoma | - |
dc.subject.keywordAuthor | Tyrosine kinase | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.